Breaking News

ANI Acquires Inderal LA Assets

March 14, 2016

Expands commercial portfolio

ANI Pharmaceuticals, Inc. has agreed to acquire a portfolio of Inderal LA assets and finished goods inventory from Cranford Pharmaceuticals, LLC. The acquisition will include the NDA and trademark for Inderal LA 60mg, 80mg, 120mg and 160mg sustained release capsules as well as the authorized generic, propranolol ER capsules, both of which are indicated for hypertension, angina pectoris, migraine and hypertrophic subaortic stenosis. According to IMS Health, Inderal LA and the authorized generic generated combined sales of $30 million in 2015.
The transaction is expected to close in the second quarter of 2016, subject to certain closing conditions. Financial terms were not disclosed.
Arthur S. Przybyl, ANI's president and chief executive officer said, "We are excited to add these extended release products to the ANI commercial portfolio. The acquisition, which is consistent with our strategy of pursuing limited competition generic products and mature brands, will be material to our revenue and EBITDA in 2016. We plan to provide updated financial guidance upon closing the transaction."

Related Packaging:

blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus